Pharmacoinvasive strategy

OTHER2 trials

Sponsors

Instituto Nacional de Cardiologia Ignacio Chavez, West China Hospital

Conditions

Myocardial Infarction, AcuteST Elevation Myocardial Infarction

Unknown Phase

Pharmacoinvasive Strategy vs. Primary PCI in STEMI: A Prospective Registry in a Large Geographical Area

CompletedNCT03974581

Instituto Nacional de Cardiologia Ignacio ChavezMyocardial Infarction, Acute

Start: 2018-04-30End: 2020-07-14Updated: 2020-07-15

Optimal Reperfusion Strategy for STEMI Patients With Anticipated PPCI Delay

West China HospitalST Elevation Myocardial Infarction

Start: 2021-03-31End: 2023-09-30Target: 632Updated: 2021-02-12

Related Papers

Abstract 17066: Efficacy and Safety of the Pharmacoinvasive Strategy Compared With Primary Percutaneous Coronary Intervention in Patients Initially Presenting to Hospital Centers Without Capacity for Coronary Intervention

Circulation2023-11-07

Time to percutaneous coronary intervention in patients with ST-elevation myocardial infarction undergoing successful systemic fibrinolysis: does early or late make a difference?

European Heart Journal Acute Cardiovascular Care2021-04-01

Efficacy and safety of pharmacoinvasive strategy compared with primary PCI in patients with STEMI presenting to non-PCI hubs: A real world study

European Heart Journal Acute Cardiovascular Care2021-04-01

Adherence and persistence of optimal medical therapy after myocardial infarction in a low to middle income country

European Heart Journal Acute Cardiovascular Care2021-04-01

Rationale and design of the <scp>OPTIMAL‐REPERFUSION</scp> trial: A prospective randomized multi‐center clinical trial comparing different fibrinolysis‐transfer percutaneous coronary intervention strategies in acute <scp>ST</scp>‐segment elevation myocardial infarction

Clinical Cardiology2021-02-258 citations